Aptose Biosciences Inc (APS : TSX)
Common Stock
$2.19
CAD
-0.14 (-6.01%)
Last updated: 2026-06-10
APS
Aptose Biosciences Inc
WealthAwesomePerformance
1 Day
-6.01%
1 Week
-0.45%
1 Month
-6.01%
YTD
+8.42%
Key Statistics
Market Cap
$5.95M
52W High
$2.59
52W Low
$1.02
P/E Ratio
-
50 Day MA
$2.30
200 Day MA
$2.09
Beta
0.29
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/10/2026 | $2.20 | $2.20 | $2.19 | $2.19 | $2.19 | 1,000 |
| 6/9/2026 | $2.19 | $2.33 | $2.19 | $2.33 | $2.33 | 5,800 |
| 6/8/2026 | $2.20 | $2.20 | $2.20 | $2.20 | $2.20 | 0 |
| 6/5/2026 | $2.20 | $2.20 | $2.20 | $2.20 | $2.20 | 100 |
| 6/4/2026 | $2.20 | $2.20 | $2.20 | $2.20 | $2.20 | 400 |
| 6/3/2026 | $2.19 | $2.20 | $2.19 | $2.20 | $2.20 | 500 |
| 6/2/2026 | $2.24 | $2.24 | $2.15 | $2.20 | $2.20 | 13,311 |
| 6/1/2026 | $2.38 | $2.38 | $2.22 | $2.26 | $2.26 | 17,424 |
| 5/29/2026 | $2.28 | $2.38 | $2.28 | $2.33 | $2.33 | 2,206 |
| 5/28/2026 | $2.28 | $2.28 | $2.20 | $2.28 | $2.28 | 6,370 |
Analyst Price Targets
Based on analyst covering APS
Wall Street analysts forecast APS stock price to rise 7.7% over the next 12 months.
Consensus
No RatingAvg. Target
C$2.36
+7.7% Upside
Current Price
C$2.19
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APS's historical volatility
30-Day Vol
67.8%
Annualized
90-Day Vol
44.0%
Annualized
Trend (90d)
+3.9%
Annualized drift
90d Mean
C$2.22
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$2.20 | C$1.74 โ C$2.78 |
| 60 trading days | C$2.21 | C$1.59 โ C$3.08 |
| 90 trading days | C$2.22 | C$1.48 โ C$3.33 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Aptose Biosciences Inc
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes. It has license agreements with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-26.42M
- Profit Margin
- 0.00%
- ROE (TTM)
- -694.13%
- EPS (Diluted)
- -15.36
- Book Value
- -18.94
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About APS
Articles Featuring APS.TO
Latest articles and analysis covering APS.TO
Why Aptose Biosciences Inc stock is plummeting today
Aptose Biosciences Inc saw a notable decline in its stock price, closing at CA$2.19, down 6.01%. This drop raises questions about the company's future prospects amidst ongoing corporate developments.
Why Aptose Biosciences Inc stock is skyrocketing today
Aptose Biosciences Inc's stock surged by 5.91% in the last trading session, closing at CA$2.33. This increase highlights investor optimism regarding the company's strategic moves and clinical advancements.
